Skip to main content
. 2023 Oct 4;37(11):2150–2167. doi: 10.1038/s41375-023-02048-y

Fig. 5. BCR::ABL1 TKD mutations.

Fig. 5

Map of ABL1 indicating the mutations reported in the literature to be associated with resistance to ATP-competitive TKIs (imatinib, dasatinib, nilotinib, bosutinib and ponatinib).